Phentermine with topiramate for the treatment of obesity and overweight
 
Status Suspended
Process STA
Referral date 01 July 2012
Topic area
  • Endocrine, nutritional and metabolic
  • Public health
  • Therapeutic procedures
Description

Scoped as part of batch 23

Provisional Schedule

Closing date for invited submissions / evidence submission: 14 November 2012
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: Andrew Dillon
Project manager: Kate Moore
Technical Lead: Pilar Pinilla-Dominguez

Consultees

Manufacturers/sponsors Vivus (phentermine with topiramate)
Others Arden PCT Cluster
  Department of Health
  Welsh Government
Patient/carer groups HEART UK
Professional groups Royal College of Nursing
  Royal College of Physicians
  The Obesity Management Association

Commentators

Associated guideline groups None
Associated public health groups None
Comparator manufacturers GlaxoSmithKline (orlistat) (confidentiality agreement not signed, not participating)
  Roche Products (Orlistat) (confidentiality agreement not signed, not participating)
  Teva UK (orlistat) (confidentiality agreement not signed, not participating)
Evidence Review Group National Institute for Health Research Health Technology Assessment Programme
  School of Health and Related Research Sheffield (ScHARR)
General Commissioning Support Appraisals Services
  Department of Health,Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
Relevant research groups Cochrane Heart Group

Timeline

Key events during the development of the guidance:

Date Update
29 April 2013

The Department of Health asked the Institute to conduct an appraisal of phentermine with topiramate for the treatment of obesity and overweight and to provide guidance on its use to the NHS in England and Wales.

The Institute has noted that the Committee for Medicinal Products for Human Use (CHMP) recently re-examined its initial negative opinion for phentermine and has confirmed the refusal of the marketing authorisation.

NICE has therefore decided to suspend this appraisal indefinitely.

As this topic has been referred to the Institute we will continue to monitor any developments and will update this webpage if the situation changes.

6 November 2012

Following an update on the regulatory status of this technology which has received a negative CHMP opinion, we are suspending the appraisal whilst we consider the next steps. Consequently the discussion of this appraisal at the Committee meeting on 27 February 2013 has been cancelled.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance